BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.88 per share, which was better than the Zacks Consensus Estimate of a loss of$1, representing an earnings surprise of 12% [1] - The company posted revenues of $116.63 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 86.76$211.12 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Since the beginning of the year, BridgeBio Pharma shares have increased by approximately 30.8%, contrasting with a decline of 6% in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of$60.98 million, and for the current fiscal year, it is -$4.18 on revenues of$255.08 million [7] - The estimate revisions trend for BridgeBio Pharma is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]